Drug Trial Radar · NCT04752826
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Jan 25, 2021
Primary completion
Jan 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- BioInvent International ABIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Feb 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1808 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials. Participants will receive infusions of with BI-1808 as a single agent, BI-1808 in combination with pembrolizumab and BI-1808 in combination with pembrolizumab and paclitaxel every 3 weeks. For the purpose of this study, subjects with advanced malignancies includes subjects with advanced solid tumors and subjects with T-cell lymphoma (TCL),
Conditions
- Advanced Malignancies
- Ovarian Cancer
- T-cell Lymphoma
- Melanoma
Interventions
BI-1808Drug
BI-1808 administered as a flat-dose IV infusion once every 3 weeks
Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for InjectionDrug
Pembrolizumab administered as a flat-dose IV infusion once every 3 weeks.
Paclitaxel 80 mg/m2 weeklyDrug
Paclitaxel administered as a flat-dose IV infusion weekly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of adverse events (AEs)Time frame: From the start of the study treatment for up to 2 years and 90 days.
- Identify DLTs, determine the maximum tolerated dose and select a recommended Phase 2 dose (RP2D) of BI-1808, given via intravenous (IV) infusion, as a single agent (Phase 1, Part A), and in combination with pembrolizumab (Phase 1, Part B)Time frame: Up to 104 weeks (2 years)
- Occurrence of serious adverse events (SAEs)Time frame: Up to 104 weeks (2 years)
- To identify the recommended Phase 2 dose (RP2D) of BI-1808,Time frame: up to 104 weeks (2 years)
Locations
25 sites in 7 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Rigshospitalet
Copenhagen, Denmark · Recruiting
Herlev Hospital
Herlev, Denmark · Recruiting
PRA Health Sciences - Hungary
Budapest, Hungary · Active not recruiting
Magyar Honvédség-Egészségügyi Központ
Budapest, Hungary · Recruiting
Debreceni Egyetem Klinikai Központ
Debrecen, Hungary · Withdrawn
Byudzhetnoye Uchrezhdeniye Zdravookhraneniya Omskoy Oblasti - Klinicheskiy Onkologicheskiy Dispanser
Omsk, Russia · Terminated
National Medical Research Center VA Almazov
Saint Petersburg, Russia · Withdrawn
N.N. Petrov National Medical Research Center of Oncology
Saint Petersburg, Russia · Withdrawn
Institut Catala d'oncologia. Hospital Duran I Reynals
Barcelona, Spain · Not yet recruiting
Hospital Universitario Puerta de Hierro-Majadahonda, Madrid,
Madrid, Spain · Not yet recruiting
START Madrid - Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Sahlgrenska University Hospital
Gothenburg, Sweden · Recruiting
Skanes University Hospital
Lund, Sweden · Recruiting
Karolinska University Hospital, Solna
Stockholm, Sweden · Recruiting
University Hospital Birmingham
Birmingham, United Kingdom · Recruiting
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom · Recruiting
Guy's and Saint Thomas' NHS Foundation Trust
London, United Kingdom · Recruiting
Sarah Cannon Research Institute UK
London, United Kingdom · Recruiting
The Royal Marsden Hospital NHS Foundation Trust
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Southampton General Hospital
Southampton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.